WATCH NOW
performance goals . Through this initiative , we aim to foster collaboration across the company , the industry and regulatory bodies . I have the honour of leading the office along with Aparna Ahuja , M . D ., Divisional Vice President for medical , clinical and scientific affairs , Infectious Disease , for Abbott ’ s rapid diagnostics business . By 2030 , Abbott ’ s goal is to build a strong model through our diversity in research efforts to eventually help 3bn people annually .
WHY IS ABBOTT COMMITTED TO DIVERSITY ? Ensuring that clinical trials are as diverse as the people a product intends to serve is critically important in providing the best healthcare , so we ’ re developing programmes to address as many barriers as possible .
At Abbott , we ’ ve implemented programmes that will increase the diversity
of trials , including assessing how we conduct our trials to ensure that we ’ re doing all we can to increase participation from underserved and under-represented populations .
PLANS FOR DIRO OVER NEXT 12-MONTHS ?
» Our goal is to ensure that clinical trials are as diverse as the people a product intends to serve – this is critically important in providing the best care . We ’ re developing educational materials for communities and partnering with organisations to expand access to new patient populations and creating resources on disease state awareness .
At Abbott , we ’ re excited to grow the initiative over the next year , especially with our first project in Louisville , Kentucky , and educate the healthcare industry on the importance of diversity in clinical trials and collaborate on ways to overcome barriers .
healthcare-digital . com 13